Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oncolytic virus
Biotech
Replimune's request for melanoma approval rejected by FDA
Investors sent the biotech’s share price down 76% to below $3 in premarket trading.
Nick Paul Taylor
Jul 22, 2025 8:45am
Theriva prioritizes oncolytic adenovirus at expense of GvHD drug
Mar 7, 2025 4:47am
4 years on from launch, IconOVir sells oncolytic virus to UroGen
Feb 20, 2025 9:12am
Candel burns bright as phase 3 cancer win sends stock up 200%
Dec 11, 2024 9:49am
Transgene's viral cancer vaccine flunks midphase test
Oct 14, 2024 4:59am
CG sets new bar in bladder cancer, months after huge IPO
May 3, 2024 11:23am